Overview

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Status:
Completed

Trial end date:
2020-02-26

Target enrollment:

Participant gender:

Summary

This is a study to compare the efficacy of bimekizumab versus adalimumab in the treatment of subjects with moderate to severe chronic plaque psoriasis (PSO).

Phase:

Phase 3

Details

Lead Sponsor:

UCB Biopharma S.P.R.L.

Treatments:

Adalimumab